The in vitro effect of new muramyl peptide derivatives on cytotoxic activity of NK (natural killer) cells from hamsters bearing Ab Bomirski melanoma.
The modulation of NK activity by muramyl dipeptides derivatives against Ab (amelanotic) Bomirski melanoma and human erythroleukemia K562 cells was studied in vitro. The stimulatory effect was observed for 3 of 7 muramyl dipeptides: MDP(L-Ala)C921, MDPC857 and L18-MDP(Ala) in relation to cytotoxic activity of NK cells obtained from peripheral blood and spleen of healthy and Ab Bomirski melanoma bearing hamsters. An increased of cytotoxic activity NK cells isolated from animals before and during the transplantable phase of the tumor against K562 was found. A similar stimulation was received for NK cells obtained from animals against their own melanoma cells. The most significant influence of examined MDP derivatives on the cytotoxic activity of NK cells were obtained from animals between 10 to 12 days of tumor growth. The extent of the modulation of cytotoxic activity of NK cells was dependent on its initial value both in healthy control and Ab Bomirski melanoma bearing hamsters. If natural cytotoxic activity was high the stimulatory effect of the examined MDP derivatives was only slightly expressed.
Sosnowska
D
D
Department of Histology and Immunology, Medical University of Gdansk, Poland.
Mysliwski
A
A
Dzierzbicka
K
K
Kolodziejczyk
A M
AM
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000031:analogs & derivatives* / Q000494:pharmacology*; D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D006224:Cricetinae; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D006801:Humans; D016219:Immunotherapy, Adoptive; D007694:Killer Cells, Natural / Q000187:drug effects* / Q000276:immunology*; D004915:Leukemia, Erythroblastic, Acute / Q000276:immunology / Q000628:therapy; D018328:Melanoma, Amelanotic / Q000276:immunology* / Q000628:therapy; D008546:Melanoma, Experimental / Q000276:immunology* / Q000628:therapy; D008647:Mesocricetus; D012878:Skin Neoplasms / Q000276:immunology* / Q000628:therapy
D000276:Adjuvants, Immunologic; D000119:Acetylmuramyl-Alanyl-Isoglutamine